ImmuPharma plc is grossly undervalued. The company’s flagship drug, Lupuzor—a potential treatment for Lupus—is currently completing a Phase 3 clinical trial which is expected to read-out top line results before the end of 2017. The drug has been looked upon favourably by US regulators, which have deemed it a priority treatment. Should the drug be approved, we estimate it could achieve multi-billion dollar annual sales. We initiate coverage with a 171p target price, indicatin
20 Jul 2016
A potential blockbuster
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
A potential blockbuster
- Published:
20 Jul 2016 -
Author:
Vadim Alexandre -
Pages:
6
ImmuPharma plc is grossly undervalued. The company’s flagship drug, Lupuzor—a potential treatment for Lupus—is currently completing a Phase 3 clinical trial which is expected to read-out top line results before the end of 2017. The drug has been looked upon favourably by US regulators, which have deemed it a priority treatment. Should the drug be approved, we estimate it could achieve multi-billion dollar annual sales. We initiate coverage with a 171p target price, indicatin